Sarepta Therapeutics

Connections 1

Description

Sarepta Therapeutics, Inc. (Nasdaq: SRPT) is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of the end of 2019, the company has two approved drugs (see the Products section below).

History

Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome (SARS) and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell.

In 2012, the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016.

In February 2019, Sarepta acquired five gene therapy candidates for $165 million after one of them, MYO-101, produced results with a new gene therapy candidate for patients with Limb-Girdle muscular dystrophy; two months after receiving a single treatment, muscles from all three patients were producing the protein they couldn't make on their own.

As of 2022, there are three FDA-approved Duchenne muscular dystrophy drugs in Sarepta Therapeutics' portfolio. In January 2023, Sarepta partnered with Catalent to manufacture delandistrogene moxeparvovec (SRP-9001).

Website

https://www.sarepta.com

Rating GlobalNY.biz

Take place №2864 In rating New York Organizations general
Take place №270 In rating Healthcare area

<!-- advertisement 10-->
<div class="mobileShow">
<script>
  atOptions = {
    'key' : '33fb986b72fdc254fb0c1e79be22e3ec',
    'format' : 'iframe',
    'height' : 250,
    'width' : 300,
    'params' : {}
  };
</script>
<script src="https://www.highperformanceformat.com/33fb986b72fdc254fb0c1e79be22e3ec/invoke.js"></script>
</div>
<div class="mobileHide">
<script>
  atOptions = {
    'key' : '60966449084d21264769e3d9bdff986a',
    'format' : 'iframe',
    'height' : 90,
    'width' : 728,
    'params' : {}
  };
</script>
<script src="https://www.highperformanceformat.com/60966449084d21264769e3d9bdff986a/invoke.js"></script>
</div>

5 July 2023

Business

Record-breaking CEO in Late 30s Outearns Apple's Tim Cook in Recent Year

Unveiling the Elite Nine Rarely do CEOs earn over $100 million in compensation, but Kiwi Camara, CE...

<!-- advertisement 12-->
<div class="mobileShow">
<script type="text/javascript">
	atOptions = {
		'key' : '33fb986b72fdc254fb0c1e79be22e3ec',
		'format' : 'iframe',
		'height' : 250,
		'width' : 300,
		'params' : {}
	};
</script>
<script type="text/javascript" src="//www.highperformanceformat.com/33fb986b72fdc254fb0c1e79be22e3ec/invoke.js"></script>
</div>
<div class="mobileHide">
<script type="text/javascript">
	atOptions = {
		'key' : '60966449084d21264769e3d9bdff986a',
		'format' : 'iframe',
		'height' : 90,
		'width' : 728,
		'params' : {}
	};
</script>
<script type="text/javascript" src="//www.highperformanceformat.com/60966449084d21264769e3d9bdff986a/invoke.js"></script>
</div>

INGRAM Douglas

President and Chief Executive Officer of the Sarepta Therapeutics
#1270

OPPENHEIM Lance

I’m excited for him to ‘have a seat’ and watch the movie in a movie theater, if that’s where he chooses to watch it.

PAUL Frankie Taylor

[I said,] ‘Yes.’ Yes, I did [get engaged]

BULLOCK Sandra

We thought, ‘This is going to be such an amazing film. People are going to love it.’ And then it got quiet. It got quiet

KAZANKOV Dmitry Alexandrovich

It works excellently in tandem with documentary genealogy: confirming or refuting hypotheses, finding unknown relatives, and breaking through brick walls. But expecting the test to build a pedigree back to the 16th century on its own is an illusion. Without archives, parish registers, and competent analysis of matches, the test remains just a set of percentages. We always advise users to first establish a documentary foundation and only then verify it with DNA data